These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 18617532)

  • 1. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans.
    Kuwahara T; Koyama A; Koyama S; Yoshina S; Ren CH; Kato T; Mitani S; Iwatsubo T
    Hum Mol Genet; 2008 Oct; 17(19):2997-3009. PubMed ID: 18617532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans.
    Kuwahara T; Tonegawa R; Ito G; Mitani S; Iwatsubo T
    J Biol Chem; 2012 Mar; 287(10):7098-109. PubMed ID: 22232559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of gene expression changes in transgenic C. elegans overexpressing human alpha-synuclein.
    Vartiainen S; Pehkonen P; Lakso M; Nass R; Wong G
    Neurobiol Dis; 2006 Jun; 22(3):477-86. PubMed ID: 16626960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans.
    Kuwahara T; Koyama A; Gengyo-Ando K; Masuda M; Kowa H; Tsunoda M; Mitani S; Iwatsubo T
    J Biol Chem; 2006 Jan; 281(1):334-40. PubMed ID: 16260788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
    Fujiwara H; Hasegawa M; Dohmae N; Kawashima A; Masliah E; Goldberg MS; Shen J; Takio K; Iwatsubo T
    Nat Cell Biol; 2002 Feb; 4(2):160-4. PubMed ID: 11813001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.
    Sapru MK; Yates JW; Hogan S; Jiang L; Halter J; Bohn MC
    Exp Neurol; 2006 Apr; 198(2):382-90. PubMed ID: 16455076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages.
    Ichibangase T; Saimaru H; Takamura N; Kuwahara T; Koyama A; Iwatsubo T; Imai K
    Biomed Chromatogr; 2008 Mar; 22(3):232-4. PubMed ID: 17939164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Synucleinopathy models and human neuropathology: similarities and differences.
    Kahle PJ
    Acta Neuropathol; 2008 Jan; 115(1):87-95. PubMed ID: 17932682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrogradely transmitted α-synuclein is taken up by the endophilin-independent endocytosis in the C. elegans neural circuit.
    Wang X; Shinkai Y; Doi M
    Biochem Biophys Res Commun; 2021 May; 552():176-182. PubMed ID: 33751935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blockade of the aberrant aggregation of alpha-synuclein in HEK293 cells induced by overexpression of wild-type alpha-synuclein by RNA interference].
    Chen T; Tang BS; Liao XP
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):128-31. PubMed ID: 18393229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein.
    Rockenstein E; Schwach G; Ingolic E; Adame A; Crews L; Mante M; Pfragner R; Schreiner E; Windisch M; Masliah E
    J Neurosci Res; 2005 Apr; 80(2):247-59. PubMed ID: 15765523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifespan extension by suppression of autophagy genes in Caenorhabditis elegans.
    Hashimoto Y; Ookuma S; Nishida E
    Genes Cells; 2009 Jun; 14(6):717-26. PubMed ID: 19469880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease.
    Häbig K; Walter M; Stappert H; Riess O; Bonin M
    Brain Res; 2009 Feb; 1256():19-33. PubMed ID: 19135032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein and transgenic mouse models.
    Fernagut PO; Chesselet MF
    Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic RNAi Screen of Neuroprotective Genes Identifies Novel Modulators of Alpha-Synuclein-Associated Effects in Transgenic Caenorhabditis elegans.
    Jadiya P; Fatima S; Baghel T; Mir SS; Nazir A
    Mol Neurobiol; 2016 Nov; 53(9):6288-6300. PubMed ID: 26567108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans.
    Kraemer BC; Burgess JK; Chen JH; Thomas JH; Schellenberg GD
    Hum Mol Genet; 2006 May; 15(9):1483-96. PubMed ID: 16600994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic neurotransmission protein UNC-13 affects RNA interference in neurons.
    Chapin A; Correa P; Maguire M; Kohn R
    Biochem Biophys Res Commun; 2007 Mar; 354(4):1040-4. PubMed ID: 17276405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clathrin interaction and subcellular localization of Ce-DAB-1, an adaptor for protein secretion in Caenorhabditis elegans.
    Kamikura DM; Cooper JA
    Traffic; 2006 Mar; 7(3):324-36. PubMed ID: 16497226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic models of alpha-synuclein pathology: past, present, and future.
    Hashimoto M; Rockenstein E; Masliah E
    Ann N Y Acad Sci; 2003 Jun; 991():171-88. PubMed ID: 12846986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.